Targets In-Depth Focus 2019
Posted: 10 December 2019 | Drug Target Review | No comments yet
The articles in this In-Depth Focus explore a novel technique for studying protein aggregation in Alzheimer’s research and explain how to maximise the potential of mass spectrometry.
Included in this in-depth focus:
- A novel approach to unravelling the mysteries of Alzheimer’s
The heterogenous and dynamic nature of protein aggregates makes them a particularly challenging class of structures to study. In this article, Professor Tuomas Knowles and Dr Sean Devenish present a novel approach to studying protein structures that could aid in understanding the complexities of Alzheimer’s disease and identify future therapeutic targets. - Advances in mass spectrometry: unlocking the potential of chemical crosslinking as a structural biology tool
Chemical crosslinking coupled with mass spectrometry (XL-MS) has been used for many years to study protein structure and function. However, recent advances in MS technology, as well as crosslinking reagents and data analysis tools, mean the technique has truly come of age. Here, Albert JR Heck, Alexander Makarov, Henning Urlaub and Vicki Wysocki look at how overcoming XL-MS workflow bottlenecks can unlock the full potential of this approach as a structural biology tool.
Related topics
Disease research, Drug Targets, Mass Spectrometry, Neurosciences, Research & Development, Targets
Related organisations
Agilent Technologies - UK
Related people
Dr Sean Devenish (Fluidic Analytics), Professor Albert JR Heck (Utrecht University and the Netherlands Proteomics Centre), Professor Alexander Makarov (Thermo Fisher Scientific), Professor Henning Urlaub (Göttingen University Medical Center), Professor Tuomas Knowles (University of Cambridge), Professor Vicki Wysocki (Ohio State University)
